Membranous nephropathy following anti–COVID-19 mRNA vaccination

Gueguen, Lorraine; Loheac, Charlotte; Saïdani, Nadia; Khatchatourian, Lydie

doi:10.1016/j.kint.2021.08.006

Cited by 30 publications

(29 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, 5 cases of MN have been reported in the literature. PLA2r antibodies were positive in three of them, and NELL1 [ 27 ] was positive in one.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

New Onset Biopsy-Proven Nephropathies after COVID Vaccination

et al. 2022

View full text Add to dashboard Cite

Introduction: To date, almost 7 billion doses of the different types of vaccine against SARS-CoV-2 have been administered worldwide. Although the severity of new cases of SARS-CoV-2 has progressively decreased, and the pressure on national health systems has declined, the development of de novo glomerular injuries has been suggested. Methods: This study aimed to examine the patients who were hospitalized in our Unit between April and November 2021 and underwent renal biopsy for new-onset urinary abnormalities (UA) and/or renal impairment within 3 months of SARS-CoV-2 vaccination. Results: We identified 17 patients who developed UA and/or renal insufficiency within 3 months of vaccination. Minimal change disease was the most common disease in our cohort (5 patients, 29.4%) followed by acute tubulointerstitial nephritis (TIN; 3 patients, 17.6%), membranous nephropathy (3 patients, 17.6%), and rapidly progressive IgA nephropathy (2 patients, 11.8%). The other 4 patients had a diagnosis of membranoproliferative glomerulonephritis (1 patient), systemic lupus erythematosus (1 patient), ANCA-associated vasculitis (1 patient), and tip-variant focal segmental glomerulosclerosis (1 patient), respectively. Eight out of the 17 patients (47.1%) developed acute kidney injury. Two patients with acute TIN had to start hemodialysis that was discontinued after 1 and 2 months, respectively, due to the recovery of renal function. All patients underwent treatment with corticosteroids and/or immunosuppressants. Discussion: Although it is not possible to conclusively determine whether there is a causal relationship between SARS-CoV-2 vaccination and new-onset nephropathies, based on the appearance of UA and/or renal insufficiency shortly after vaccination, we hypothesize that the immune response to the COVID-19 vaccine may be a trigger of nephropathies. Therefore, our results highlight the need for pharmacovigilance. However, this report should not lead to vaccine hesitation during this pandemic as the benefits of vaccination strongly outweigh the potential risks.

show abstract

“…To date, 5 cases of MN have been reported in the literature. PLA2r antibodies were positive in three of them, and NELL1 [ 27 ] was positive in one.…”

Section: Discussionmentioning

confidence: 99%

“…This prevalence is confirmed in our cohort. Other authors have published reports on new-onset IgAN [ 23 , 24 , 25 , 26 ], MN [ 23 , 27 , 28 ], FSGS [ 23 ], and systemic vasculitis [ 29 ]. All these glomerular diseases were represented in our cohort.…”

Section: Discussionmentioning

confidence: 99%

New Onset Biopsy-Proven Nephropathies after COVID Vaccination

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Glomerular diseases mentioned in association with COVID-19 vaccines include IgA nephropathy [ 10 ], podocytopathies [ 10 ], lupus nephritis [ 21 ], crescentic glomerulonephritis, anti-GBM disease [ 10 ], IgG4 disease [ 22 ], and membranous nephropathy [ 23 ]. In an observational study from Japan [ 24 ], where IgA nephropathy is more prevalent and diagnosed earlier in life than the rest of the world, gross haematuria and proteinuria on screening urine examination post-vaccination have led to the identification of recurrence and new-onset IgA nephropathy associated with COVID-19 vaccination.…”

Section: Discussionmentioning

confidence: 99%

ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review

et al. 2022

View full text Add to dashboard Cite

For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity. Supplementary Information The online version contains supplementary material available at 10.1007/s00296-021-05069-x.

show abstract

“…As of 28 February 2022, we found a total of 38 published articles (53 cases) on AKI after SARS-CoV-2 vaccination ( Table 1 ) [ 11 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ]. Only one case clearly identified an increase in Scr and a resolve within 7 days after vaccination [ 30 ].…”

Section: Clinical Characteristics Of Patientsmentioning

confidence: 99%

New-Onset Acute Kidney Disease Post COVID-19 Vaccination

Rao

2022

Vaccines

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused an exceptional setback to the global economy and health. Vaccination is one of the most effective interventions to markedly decrease severe illness and death from COVID-19. In recent years, there have been increasingly more reports of new acute kidney injury (AKI) after COVID-19 vaccination. Podocyte injury, IgA nephropathy, vasculitis, tubulointerstitial injury, and thrombotic microangiopathy appear to be the main pathological phenotypes. Nonetheless, whether the link between the COVID-19 vaccine and acute kidney disease (AKD) is causal or coincidental remains to be verified. Here, we generalize some hypotheses for the emergence of AKD and its pathogenesis in response to certain COVID-19 vaccines. In fact, the enormous benefits of mass vaccination against COVID-19 in preventing COVID-19 morbidity and mortality cannot be denied. The purpose of this review is to assist in the clinical assessment and management of AKD following COVID-19 vaccination.

show abstract

Membranous nephropathy following anti–COVID-19 mRNA vaccination

Cited by 30 publications

References 3 publications

New Onset Biopsy-Proven Nephropathies after COVID Vaccination

New Onset Biopsy-Proven Nephropathies after COVID Vaccination

ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review

New-Onset Acute Kidney Disease Post COVID-19 Vaccination

Contact Info

Product

Resources

About